Psychostimulant-related targets

Psychostimulant-related targets comprise a group of proteins primarily involved in the regulation of monoamine neurotransmitters, including dopamine, norepinephrine, and serotonin. The most prominent members of this group are the solute carrier family 6 (SLC6) transporters, specifically the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) [1][2]. These proteins are responsible for the reuptake of neurotransmitters from the synaptic cleft, thereby controlling the duration and intensity of signaling. Additionally, the vesicular monoamine transporter 2 (VMAT2) and the trace amine-associated receptor 1 (TAAR1) play critical roles in the storage and release of these amines [3][4]. Psychostimulants like cocaine and amphetamines interact with these targets to increase extracellular monoamine concentrations, particularly in the brain's reward and arousal circuitry [5]. Beyond transporters, this group includes various G protein-coupled receptors, such as dopamine D1 and D2 receptors, which mediate the downstream effects of increased transmitter levels [2]. Dysregulation of these targets is central to the pathophysiology of attention deficit hyperactivity disorder (ADHD), narcolepsy, and substance use disorders [5][6]. Therapeutic agents targeting these proteins are used to improve focus and wakefulness, but they also carry significant risks of cardiovascular strain and psychological dependence [2][6]. Sources: [1] UniProt: SLC6A3 (P23975), SLC6A2 (P23975), SLC6A4 (P31645). [2] StatPearls: Physiology, Dopamine (NBK539815). [3] PubChem: Trace Amine-Associated Receptor 1 (TAAR1). [4] PubMed: "Mechanism of action of psychostimulants" (Volkow et al., 2011). [5] NIH/NIDA: "Impact of Stimulants on the Brain" (DrugFacts). [6] FDA: Prescribing Information for Adderall and Ritalin (Safety and Indications).

Other names

Monoamine transportersStimulant targetsDopaminergic targetsMonoaminergic targetsSympathomimetic targets

Inhibition of monoamine reuptake via competitive or non-competitive binding to plasma membrane transporters (DAT, NET, SERT) and induction of neurotransmitter efflux through the reversal of transporter directionality, often mediated by VMAT2 inhibition and TAAR1 agonism.